Literature DB >> 17047119

Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease.

B Beltrán, P Nos, G Bastida, M Iborra, M Hoyos, J Ponce.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17047119      PMCID： PMC1860084          DOI： 10.1136/gut.2006.101386

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  8 in total

1.  Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.

Authors:  R E Walker; K M Spooner; G Kelly; R V McCloskey; J N Woody; J Falloon; M Baseler; S C Piscitelli; R T Davey; M A Polis; J A Kovacs; H Masur; H C Lane
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

2.  [Subclinical Crohn disease in acquired immunodeficiency syndrome].

Authors:  D Moreno Sánchez; J A Solís Herruzo; J Medina Asensio; J Vargas Castrillón; F Colina Ruiz-Delgado
Journal:  Rev Esp Enferm Dig       Date:  1993-12       Impact factor: 2.086

3.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

4.  A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.

Authors:  Robert S Wallis; Peter Kyambadde; John L Johnson; Libby Horter; Rodney Kittle; Monika Pohle; Constance Ducar; Monica Millard; Harriet Mayanja-Kizza; Christopher Whalen; Alphonse Okwera
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

5.  Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.

Authors:  Beverly E Sha; Hernan Valdez; Rebecca S Gelman; Alan L Landay; Jan Agosti; Ronald Mitsuyasu; Richard B Pollard; Donna Mildvan; Ann Namkung; Debra M Ogata-Arakaki; Lawrence Fox; Scharla Estep; Alejo Erice; Patrick Kilgo; Robert E Walker; Lynne Bancroft; Michael M Lederman
Journal:  AIDS Res Hum Retroviruses       Date:  2002-06-10       Impact factor: 2.205

6.  Accelerated course of human immunodeficiency virus infection after tuberculosis.

Authors:  C Whalen; C R Horsburgh; D Hom; C Lahart; M Simberkoff; J Ellner
Journal:  Am J Respir Crit Care Med       Date:  1995-01       Impact factor: 21.405

7.  Crohn's ileitis in a patient with longstanding HIV infection.

Authors:  B B Bernstein; A Gelb; R Tabanda-Lichauco
Journal:  Am J Gastroenterol       Date:  1994-06       Impact factor: 10.864

8.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

Authors:  H M van Dullemen; S J van Deventer; D W Hommes; H A Bijl; J Jansen; G N Tytgat; J Woody
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682
  8 in total
  7 in total

1.  Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?

Authors:  Jason J Emer
Journal:  J Clin Aesthet Dermatol       Date:  2009-04

Review 2.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

3.  Successful treatment of severe perianal Crohn's disease with infliximab in an HIV-positive patient.

Authors:  Maria Ana Rafael; Luís Carvalho Lourenço; Ana Maria Oliveira; Teresa Branco; Carla Carneiro; Ana Costa; Jorge Reis
Journal:  Clin J Gastroenterol       Date:  2019-05-20

Review 4.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 5.  Tumor necrosis factor blockade and the risk of viral infection.

Authors:  Seo Young Kim; Daniel H Solomon
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

6.  Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression.

Authors:  Andrea Lisco; Chun-Shu Wong; Silvia Lucena Lage; Itzchak Levy; Jason Brophy; Jeffrey Lennox; Maura Manion; Megan V Anderson; Yolanda Mejia; Christopher Grivas; Harry Mystakelis; Peter D Burbelo; Ainhoa Perez-Diez; Adam Rupert; Craig A Martens; Sarah L Anzick; Caryn Morse; Shanna Chan; Claire Deleage; Irini Sereti
Journal:  JCI Insight       Date:  2019-04-18

7.  Trends and outcomes of fungal infections in hospitalized patients of inflammatory bowel disease: a nationwide analysis.

Authors:  Kamran Mushtaq; Zubair Khan; Muhammad Aziz; Zakaria Abdullah Alyousif; Nauman Siddiqui; Muhammad Ali Khan; Ali Nawras
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.